EU Committee Recommended Bladder Cancer Treatment
The EMA backed a combined regimen of Keytruda and Padcev for patients facing muscle-invasive bladder cancer.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Should regulatory bodies accelerate approval processes for new combination cancer therapies?
A European Medicines Agency committee has endorsed the use of Keytruda in combination with Padcev to treat muscle-invasive bladder cancer. This regimen, which utilizes a subcutaneous version of Keytruda, is intended for patients undergoing radical cystectomy.
Why it matters
The recommendation follows promising results from the Phase 3 KEYNOTE-B15 study, which demonstrated that the therapy significantly lowers the risk of disease progression and death compared to standard care.
Clinical trial data showed the combination reduced the risk of event-free survival events by 47% and lowered the risk of death by 35%. These findings stem from the Phase 3 KEYNOTE-B15 study comparing the novel regimen to standard chemotherapy.
The players
European Medicines Agency
This is the regulatory body responsible for the scientific evaluation and supervision of medicines for human use across the European Union.
Merck
This multinational pharmaceutical company develops and manufactures the oncology drug Keytruda.
The details
The treatment is designed as both a neoadjuvant and adjuvant therapy for patients preparing for surgery. By utilizing subcutaneous administration, the regimen aims to improve outcomes for those diagnosed with muscle-invasive bladder cancer.
Timeline
June 2026: The European Commission authorized the regimen for cisplatin-ineligible patients.
July 2026: The U.S. FDA cleared the combination therapy for use.
Q4 2026: The European Commission is expected to issue a final marketing authorization decision.
Health Landscape
This recommendation marks a significant evolution in bladder cancer treatment by shifting toward combined neoadjuvant and adjuvant regimens. It reflects an ongoing trend in oncology to combine immunotherapies like Keytruda with targeted agents to improve pathologic response rates.
Patients facing muscle-invasive bladder cancer may soon gain access to a combination therapy that significantly improves the probability of a pathologic complete response compared to traditional chemotherapy. This development offers a new pathway for those undergoing radical cystectomy.
The takeaway
Patients and their clinical teams should monitor updates regarding the final European Commission approval to understand potential timing for therapy access. This progress underscores the growing efficacy of using subcutaneous immunotherapy combinations in surgical oncology.
What happens next
The European Commission is expected to issue a final marketing authorization decision by the fourth quarter of 2026, which will formalize the availability of the treatment across the European Union, Iceland, Liechtenstein, and Norway.
Further reading
For more information on current treatment standards and ongoing research, explore the Cancer section.
Live Poll
Should regulatory bodies accelerate approval processes for new combination cancer therapies?
